Partner Headlines - LLY

  1. Market Wrap For April 14: Markets Surge on Positive Retail Data, ...

    Benzinga
  2. Lilly, Takeda must pay $9 bil

    IBD
  3. Ethical Drug Stocks Are Struggling

    IBD
  4. UPDATE: BMO Capital Upgrades Eli Lilly

    Benzinga
  5. Takeda, Lilly to 'Vigorously Challenge' Actos Ruling

    FoxBusiness
  6. Benzinga's Top Upgrades

    Benzinga
  7. Takeda Responds to $6B Verdict in Diabetes Drug Case

    Benzinga
  8. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  9. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  10. Market Wrap For April 3: Markets Winning Streak Fails To Extend ...

    Benzinga
  11. Wide Moat Stocks: Protection In A Correction

    YCharts
  12. UPDATE: Cowen & Company Upgrades Eli Lilly

    Benzinga
  13. Benzinga's Top Upgrades

    Benzinga
  14. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  15. Lilly Expands Generic Deal With Prasco

    FoxBusiness
  16. UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following ...

    Benzinga
  17. Merck Snags Baxter Executive As CFO

    FoxBusiness
  18. Box, Online Storage Service Provider, Files For IPO

    IBD
  19. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  20. Forest Laboratories' Recovery

    GuruFocus
  21. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  22. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  23. Elanco Announces Agreement to Acquire Lohmann Animal Health; ...

    Benzinga
  24. Actavis Q4 Beats Street; Guidance Affirmed For Now

    IBD
  25. Eli Lilly up on lung cancer trial

    IBD
  26. Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends ...

    Benzinga
  27. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD
  28. Stocks Stage Quiet, Mixed Open; Eli Lilly Up, U.S. Steel Tanks

    IBD
  29. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  30. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil ...

    Benzinga
  31. Eli Lilly

    IBD
  32. Market Wrap For January 30: Markets Focus on Good News

    Benzinga
  33. Lilly's Cymbalta to Trigger 'Severe' Sales Slide

    FoxBusiness
  34. UPDATE: Eli Lilly Posts Drop In Q4 Profit

    Benzinga
  35. #PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By ...

    Benzinga
  36. Tug Of War In Ariad Pharmaceuticals

    Benzinga
  37. Benzinga's M&A Chatter for Monday January 27, 2014

    Benzinga
  38. Income + Value Investing: YCharts Sector Report

    YCharts
  39. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  40. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  41. Is The Market On Drugs?

    Benzinga
  42. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  43. Wide Moat Stocks Against Two Value Systems

    YCharts
  44. Biogen, Celgene Lead 5 Top Large-Cap Drugmakers

    IBD
  45. Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus ...

    Benzinga
  46. Bulls Charge the Street: S&P Snaps 3-Day Losing Streak

    FoxBusiness
  47. Celgene Gets Good News On Two Cancer Drugs; Stock Up

    IBD
  48. Wall Street Climbs on Trade Data, Yellen Optimism

    FoxBusiness
  49. Eli Lilly Projects In-Line '14 Profit Slump

    FoxBusiness
  50. Stock Futures Jump Amid Fed Optimism

    FoxBusiness
  51. Drugmaker Aptalis Files For IPO After Overhaul

    IBD
  52. New ED Drug: Analysis of Vivus’s Prospects

    YCharts
  53. ObamaCare = Drug Maker Assistance Act

    YCharts
  54. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  55. US Stock Futures Gain Ahead Of GDP Data

    Benzinga
  56. PeptiDream Announces Collaboration, License Agreement with Lilly ...

    Benzinga
  57. Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus

    IBD
  58. AstraZeneca Buys Out Bristol-Myers' Diabetes Business

    IBD
  59. AstraZeneca to Buy Bristol's Stake in Joint Venture

    FoxBusiness
  60. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  61. Guru Stocks at 52-Week Lows: IBM, T, TLK, LLY, GLD

    GuruFocus
  62. End Of Antibiotics In Meat?

    IBD
  63. Citron Pharma Launches Generic Cymbalta Delayed Release Capsules ...

    Benzinga
  64. Why Pfizer’s Expiring Viagra Patent Hurts Lilly Most

    YCharts
  65. FDA Asks Meat Industry to Stop Using Antibiotics in Animal Feed

    FoxBusiness
  66. The 'Accidental CEO': Eli Lilly's Lechleiter

    FoxBusiness
  67. Health Care Heartiest, Gold Funds All Red In November

    IBD
  68. Recent Cloud IPO Veeva Systems Scores In Health Biz

    IBD
  69. Biogen, Gilead, Celgene Drugs Get Thumbs Up In Europe

    IBD
  70. Icahn stake boosts Hologic

    IBD
  71. Icahn's Buy Into Hologic Welcomed By Wall Street

    IBD
  72. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus
  73. QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic ...

    Benzinga
  74. Lilly Pumps $700M into Insulin Manufacturing

    FoxBusiness
  75. US Stock Futures Mixed Ahead of Economic Data

    Benzinga
  76. Lilly to Invest $700M to Enhance Global Insulin Manufacturing ...

    Benzinga
  77. UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative ...

    Benzinga
  78. US Stock Futures Mixed After Friday Rally

    Benzinga
  79. AbbVie’s AndroGel Testosterone Hit By Heart Study

    YCharts
  80. List: $34B In Pharma Sales Lose Patent in 2014

    YCharts
  81. Prolific Selling - Hussman's High-Impact Moves Mirror Insiders

    GuruFocus
  82. Merck falls on competition

    IBD
  83. Penny-Wise, Pharma-Foolish: Upshot of R&D Cuts

    YCharts
  84. UPDATE: FDA Approves Addition to Cialis Product Label

    Benzinga
  85. Cost cuts boost Eli Lilly profit

    IBD
  86. Stocks Futures Trim Losses; Corning, Apollo Group Spike

    IBD
  87. Benzinga's Top Pre-Market Gainers

    Benzinga
  88. US Stock Futures Down Ahead Of Earnings

    Benzinga
  89. UPDATE: Eli Lilly Q3 Profit Drops 9.3%

    Benzinga
  90. FDA Grants Priority Review to Lilly's Ramucirumab

    Benzinga
  91. Earnings Scheduled For October 23, 2013

    Benzinga
  92. Stocks To Watch For October 23, 2013

    Benzinga
  93. United Therapeutics Aims For A Cardiovascular Drug OK

    IBD
  94. Earnings Expectations For The Week Of October 21: The Crunch ...

    Benzinga
  95. Growth Stocks Glitter As S&P 500 Flirts With All-Time High

    IBD
  96. Major Averages Hold Strong Gains; IPO Veeva Systems Soars

    IBD
  97. Veeva Systems IPO Pops For Cloud Software Company

    IBD
  98. Market Primer: Friday, October 11: Budget Showdown Could Be Nearing ...

    Benzinga
  99. Lilly planning deep cost cuts

    IBD
  100. Eli Lilly Warns of '14 Revenue Headwinds

    FoxBusiness
Trading Center